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Clinical InvestigationSmoking cessation and risk of recurrent
cardiovascular events and mortality after a
first manifestation of arterial disease
M. Johanneke van den Berg, MD, a,b Yolanda van der Graaf, MD, PhD, c Jaap W. Deckers, MD, PhD, d
Wanda de Kanter, MD, e Ale Algra, MD, PhD, f,g L. Jaap Kappelle, MD, PhD, g Gert J. de Borst, MD, PhD, h
Maarten-Jan M. Cramer, MD, PhD, i and Frank L. J. Visseren, MD, PhD a ,
on behalf of the SMART study group Utrecht, Amsterdam, Rotterdam, The NetherlandsAims To quantify the relation between smoking cessation after a first cardiovascular (CV) event and risk of recurrent CV
events and mortality.
Methods Data were available from 4,673 patients aged 61 ± 8.7 years, with a recent (≤1 year) first manifestation of
arterial disease participating in the SMART-cohort. Cox models were used to quantify the relation between smoking status and
risk of recurrent major atherosclerotic cardiovascular events (MACE including stroke, MI and vascular mortality) and mortality.
In addition, survival according to smoking status was plotted, taking competing risk of non-vascular mortality into account.
Results A third of the smokers stopped after their first CV event. During a median of 7.4 (3.7–10.8) years of follow-up, 794
patients died and 692 MACE occurred. Compared to patients who continued to smoke, patients who quit had a lower risk of
recurrent MACE (adjusted HR 0.66, 95% CI 0.49–0.88) and all-cause mortality (adjusted HR 0.63, 95% CI 0.48–0.82). Patients
who reported smoking cessation on average lived 5 life years longer and recurrent MACE occurred 10 years later. In patients with a
first CV event N70 years, cessation of smoking had improved survivalwhich on averagewas comparable to former or never smokers.
Conclusions Irrespective of age at first CV event, cessation of smoking after a first CV event is related to a substantial
lower risk of recurrent vascular events and all-cause mortality. Since smoking cessation is more effective in reducing CV risk
than any pharmaceutical treatment of major risk factors, it should be a key objective for patients with vascular disease. (Am
Heart J 2019;213:112-22.)The percentage of smokers at time of first clinical
manifestation of cardiovascular (CV) disease ranges
between 30–50%.1,2 Although the harmful effects of
smoking on health are widely known,3-5 smoking is
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https://doi.org/10.1016/j.ahj.2019.03.019even after a life-threatening vascular event. A third of the
patients with cerebrovascular disease and a quarter of
patients with coronary artery disease (CAD) do not
(intent to) quit after a CV event.6,7 In patients with
peripheral artery disease, this proportion is most likely
even higher.8 In the last 15 years, the proportion of
smokers has only decreased slightly, from 20% to 16% in
2013 in European patients with CAD according to the
EUROASPIRE surveys.9 Due to better treatment options,
survival after a first CV event has increased and thus the
number of patients with a history of manifest arterial
disease.10,11 Smoking cessation appears to be more
effective in reducing CV risk than pharmaceutical
treatment of major risk factors such as cholesterol and
blood pressure or the use of antiplatelet therapy.12
Although presence of CV disease was not taken into
account, the British Doctors Study and a more recent study
based on theUnited StatesHealth InterviewSurvey showed
that cessation of smoking, even at the age of 60, was related
to improved survival with an average gain of 3 years
compared to patients who continued smoking.13,14 In
patients aged ≥65 years, admitted for acute myocardial
infarction between 1994 and 1996, cessation of smoking
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to improve survival with 1 year.15 Though mainly studied
in patients with CAD, cessation of smoking is likely to also
result in increased life expectancy in patients with other
manifestations of arterial disease. Insight and quantification
of the potential gain in life years would be helpful in
stimulating doctors to better motivate patients to quit
smoking, also after onset of CV disease.
The aimof the present study therefore is twofold. First, to
describe the prevalence and characteristics of patients after
a recent first manifestation of arterial disease according to
smoking status. Second, to quantify the relation between
smoking status and risk of recurrent CV events and
mortality, in a contemporary cohort of patients with a
variety of arterial diseasemanifestations, taking age at onset
of a first CV event and type of vascular disease into account.
Methods
Study population
Data were used from the Second Manifestations of
ARTerial disease (SMART) study, which is an ongoing
prospective cohort study at the University Medical Center
Utrecht, the Netherlands. No extramural funding was
used to support this work. The authors are solely
responsible for the design and conduct of this study, all
study analyses, the drafting and editing of the paper and
its final contents. A detailed description of the study
rationale and design has been published earlier.16
Patients were enrolled after they had reached a stable
situation in the course of their disease. For the present
study (Flowchart presented in Figure 1), data were used
from 4,673 patients aged ≥45 years, with complete
smoking status at baseline who enrolled between
September 1996 till March 2015 with a recent (within 1
year prior to baseline) first diagnosis of manifest arterial
disease, e.g. cerebrovascular disease, coronary artery
disease, peripheral artery disease or aneurysm of the
abdominal aorta (definitions can be found in Supplemental
Table 1). At inclusion patients completed a health
questionnaire, which included questions regarding
medical health and lifestyle and underwent a standardized
vascular screening.
Assessment of smoking status
Smoking behavior was classified into four categories:
‘never smoked’, ‘former smoker’ (someone who stopped
smoking prior to the vascular event), ‘quit after vascular
event’ (someone who stopped smoking in the same year
or in year after the vascular event) or ‘continued after
vascular event’. The number of pack-years was calculated
at baseline, with one pack-year defined as smoking 20
cigarettes a day for 1 year. In addition the age at which a
person stopped smoking was recorded. In former
smokers, the time (in years) between smoking cessation
and the vascular event was calculated.Assessment of covariates
Level of education was assessed at inclusion and based
on highest level of completed education and classified
into three categories; low (intermediate secondary
education or less), moderate (intermediate vocational or
high secondary education) and high (higher vocational
education or university). The definition of diabetes
mellitus is provided in Supplemental Table 1. Body
mass index was calculated as weight (kg) divided by
height (m) squared (kg/m2). Office blood pressure was
measured with a non-random sphygmomanometer and
the average of multiple measurements was taken. Plasma
lipids and high-sensitivity C-reactive protein (hs-CRP)
were measured. LDL-C was calculated using the Friede-
wald formula17 up to a plasma TG level of 9 mmol/l.18
The estimated glomerular filtration rate (eGFR) was
calculated with CKD-EPI formula.19 Medication use,
specifically use of anti-platelets and anticoagulants,
blood pressure lowering and cholesterol lowering
medication was recorded.
Assessment of outcome during follow-up
From baseline onwards, patients were asked to
biannually fill in a short questionnaire regarding hospi-
talization and outpatient clinic visits. If a patient, family
member or general practitioner reported a potential
event, relevant data were collected and an outcome
committee of three staff members assessed whether the
outcome did occur. Outcomes of interest were first,
major atherosclerotic cardiovascular events (MACE), a
composite of stroke, myocardial infarction and CV
mortality. Second, a composite of MACE and vascular
interventions, such as open or percutaneous revascular-
ization procedures and amputation of extremities (de-
scribed in more detail in Supplemental Table 2) and third,
all-cause mortality. If a patient had multiple atheroscle-
rotic events, the first recorded event was used in the
analyses. Follow-up duration was defined as the period
between enrollment and first recurrent CV event, death
from any cause, date to loss of follow-up or the
preselected date of March 2015.
Reassessment of baseline measures
From January 2006 onwards, participants with a follow-
up of at least 4 years were invited for reassessment of all
baseline measurements (SMART-2). Approximately 49%
of the patients invited for SMART-2 responded and were
reassessed. In addition, from October 2015 till March
2016, all participants received an additional questionnaire
(SMART-3) with similar questions regarding health and
lifestyle. Non-responders received one reminder, which
resulted in a total response rate of 79%. Phone calls were
made to 284 participants to complete data of returned
questionnaires with missing values, which succeeded in
70%. Smoking status during follow-up was reassessed at
SMART-2 and SMART-3 and recorded into the following
Figure 1
Flowchart of selection of study population and stratification into smoking status.
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smoking prior to the vascular event, ‘stopped after vascular
event’, ‘started or relapsed, and quit smoking after vascular
event’ or ‘continued after vascular event’.
Data analyses
The proportions of patientswhowere “never”, “former”,
“quit after vascular event” or “continued after vascular
event” smokers were calculated, also according to type of
vascular disease and year of inclusion in the SMART-study
to detect possible temporal changes. To detect possible
misclassification in smoking status, the proportions and
change in smoking status during follow-up was also
calculated in the subset of patients who participated in
SMART-2 or SMART-3. Patient characteristics of the study
population are presented according to smoking status
at baseline.
Single imputation (performed with the ‘AregImpute’
function of the ‘Hmisc’ package in R) was used to reducemissing covariate data. Variables with missing values
were: level of education (43%) since it was recorded at
baseline from 2004 onwards, BMI (b1%), Systolic blood
pressure (b1%).
Three pre-specified sets of models were used, to
analyze the effect of smoking status, in particular smoking
cessation after a first CV event, on risk of (1) recurrent
MACE, (2) recurrent MACE including vascular interven-
tions and (3) all-cause mortality.
First, Cox proportional hazards models with time since
event were used to calculate risk of the above mentioned
outcomes of interest, according to smoking status at
baseline. Hazard ratios with 95% confidence intervals
(HR, 95%CI) were adjusted for potential confounders: age,
sex, level of education (low, moderate or high), type of
vascular disease (cerebrovascular disease, coronary artery
disease, aneurysm of abdominal aorta, peripheral artery
disease or polyvascular disease), systolic blood pressure,
LDL-cholesterol, diabetes, BMI, (log transformed) hs-CRP,
Table I. Patient characteristics according to smoking status at baseline (n = 4,673)
Continued after vascular event Quit after vascular event Former smoker Never smoked
962 (21%) 544 (12%) 2144 (46%) 1023 (22%)
Age (years) 57.9 (8.3) 57.2 (7.8) 62.5 (8.4) 62.4 (8.8)
Male sex 676 (70%) 399 (73%) 1664 (78%) 627 (61%)
pack-years* 29.7 (15.7-42.3) 32.4 (10.2-46.2) 15.0 (6.6-29.4) NA
Age smoking cessation NA 57 (51-63) 45 (35-55) NA
Level of education – Low 175 (43%) 88 (28%) 378 (29%) 183 (29%)
Level of education – Moderate 165 (40%) 145 (45%) 520 (40%) 218 (34%)
Level of education – High 71 (17%) 86 (27%) 412 (31%) 239 (37%)
Medical history and medication use
Diabetes mellitus 132 (14%) 64 (12%) 327 (15%) 164 (16%)
Cerebrovascular disease 259 (27%) 130 (24%) 568 (26%) 280 (27%)
Coronary artery disease 291 (30%) 281 (52%) 1187 (55%) 643 (63%)
Aneurysm of abdominal aorta 53 (6%) 18 (3%) 95 (4%) 14 (1%)
Peripheral artery disease 309 (32%) 85 (16%) 196 (9%) 59 (6%)
Polyvascular disease 50 (5%) 30 (6%) 98 (5%) 27 (3%)
Antiplatelet/anticoagulant therapy 688 (72%) 429 (79%) 1808 (84%) 881 (86%)
Blood pressure-lowering therapy 548 (57%) 384 (71%) 1644 (77%) 819 (80%)
Statin therapy 489 (51%) 359 (66%) 1468 (68%) 704 (69%)
Measurements
Body mass index (kg/m2) 26.1 (4.4) 26.8 (4.0) 26.9 (3.6) 26.6 (3.8)
LDL-cholesterol (mmol/l) 3.2 (1.1) 2.9 (1.0) 2.8 (1.0) 2.8 (1.0)
eGFR (CKD-EPI) 83 (70 - 94) 81 (69 - 92) 76 (64 - 87) 74 (63 - 85)
Hs-CRP (mg/l) 3.1 (1.5 – 6.1) 2.0 (1.1 – 4.1) 1.8 (0.9 – 3.9) 1.5 (0.7 – 3.2)
Data are presented as number (%), mean (standard deviation) or median (interquartile range). * A pack-year is defined as smoking 20 cigarettes a day for one year. Abbreviations
LDL-C: low-density lipoprotein-cholesterol, eGFR (CKD-EPI): estimated glomerular filtration rate calculated with the CKD-EPI formula, hs-CRP: high sensitivity C-reactive protein.
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event were used as reference. In addition, HR were
adjusted for health seeking behavior, that is use of
preventative medication; anti-thrombotics (anti-platelets
and anti-coagulants), cholesterol lowering mediation and
blood pressure lowering medication. Since smoking
patterns could have changed over time, HR were also
adjusted for year of enrollment. Interaction on a multipli-
cative scale was tested for sex, level of education, type of
vascular disease with smoking status for risk of recurrent
MACE. Analyses were subsequently stratified when inter-
action was present.
Second, cumulative incidence curves were created.
These were based on Cox proportional hazard models
and accounted for non-vascular mortality by applying
the Fine-Gray comping risk method.20 Instead of follow-
up time, age at enrolment and age at event were used.
This was done in the total study population and in
patients aged ≥60 and ≥70 years at time of first CV
event. Models were adjusted for previous mentioned
confounders. A sensitivity analysis was done in which
the effect of smoking status on recurrent MACE free
survival was stratified for type of vascular disease at
baseline. Due to limited number of patients (n = 266)
and events (n = 81), this could not be done in patients
with an aneurysm of the abdominal aorta. The
assumption of proportionality was visually checked by
plotting Schoenfeld residuals. Third, to quantify a possibleexposure-response relationship, Cox models were made
with restricted cubic splines to enable a non-linear effect
of pack-years, age at smoking cessation and time
between smoking cessation and first CV event on risk
of recurrent MACE and all-cause mortality. Models were
first adjusted for age, sex, type of vascular disease, level
of education and subsequently also adjusted for the other
smoking characteristics; pack-years, age at smoking
cessation and time between smoking cessation and first
CV event respectively.
Analysis were performed with R statistical software,
version 3.3.2 (R Core Team (2016) www.R-project.org/)
with the add-on packages ‘Hmisc”, ‘rms', ‘cmprsk’ and
‘survival’.Results
Smoking status
At the time of the first CV event, 22% of patients had
never smoked, 46% was a former smoker and 32%
smoked cigarettes. Approximately a third of the smokers
(12% of the total population) quit after the vascular event
while two-thirds (21% of the total population) persisted
to smoke (Figure 1). Importantly, the distribution of
smoking status changed considerably during the course
of the study, from 1996 through 2015 (Supplemental
Figure 1A). The number of never smokers increased
(from 15% to 28%), while the proportion of persistent
Table II. Smoking status and risk of recurrent cardiovascular events and mortality
At risk Events Model 1 Model 2 Model 3
Recurrent cardiovascular events
Continued smoking after vascular event 962 198 1 1 1
Quit smoking after vascular event 544 62 0.59 (0.45-0.79) 0.64 (0.48-0.86) 0.66 (0.49-0.88)
Former smoker 2144 308 0.57 (0.47-0.68) 0.66 (0.54-0.80) 0.68 (0.56-0.83)
Never smoker 1023 124 0.50 (0.39-0.63) 0.59 (0.46-0.75) 0.59 (0.46-0.76)
Recurrent MACE including vascular interventions
Continued smoking after vascular event 962 448 1 1 1
Quit smoking after vascular event 544 181 0.71 (0.60-0.84) 0.79 (0.66-0.94) 0.81 (0.68-0.96)
Former smoker 2144 734 0.66 (0.58-0.74) 0.80 (0.70-0.91) 0.82 (0.72-0.93)
Never smoker 1023 277 0.51 (0.44-0.60) 0.66 (0.56-0.78) 0.67 (0.57-0.79)
All-cause mortality
Continued smoking after vascular event 962 260 1 1 1
Quit smoking after vascular event 544 73 0.55 (0.43-0.72) 0.62 (0.48-0.81) 0.63 (0.48-0.82)
Former smoker 2144 331 0.40 (0.34-0.48) 0.52 (0.44-0.63) 0.53 (0.44-0.63)
Never smoker 1023 130 0.34 (0.27-0.42) 0.43 (0.34-0.55) 0.43 (0.34-0.55)
Model 1: adjusted for age, sex, Model 2: model 1 additionally adjusted for level of education, type of vascular disease, diabetes, BMI, systolic blood pressure, LDL-C, and health
seeking behavior (use of antiplatelet/anticoagulant, blood pressure lowering medication and statins) and log transformed hs-CRP. Model 3: Model 2 additionally adjusted for year of
enrolment in the SMART study.
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peripheral artery disease (61%), with an aneurysm of the
abdominal aorta (39%) or with polyvascular disease (39%)
were most likely to smoke at the onset of their CV disease
manifestation. In addition, these patients were less likely
to quit smoking after the vascular event; only 22%, 25%
and 38% respectively did so while, among the patients
with cerebrovascular disease half of the smokers quitted
the habit after the vascular event (Supplemental Figure 1B,
Supplemental Table 3).
Baseline characteristics according to smoking status
The average age of the study population was 61 ±
8.7 years, and three-quarter was male. Patients who quit
smoking after the vascular event or persisted smoking were
approximately 5 years younger than the never or former
smokers (Table I). Patientswho continued to smoke after the
vascular event were more likely to have a lower level of
education, a history of PAD and were less likely to use
preventative medication.
Smoking cessation or continuation and risk of
recurrent MACE
During a median follow-up of 7.4 (interquartile range
3.7–10.8) years, 794 (17%) patients died, of which 377
(47%) of a vascular cause, 379 (48%) of a non-vascular
and 38 (5%) of an unknown cause. MACE occurred in
692 (15%) patients and MACE including vascular
interventions occurred in 1640 (35%) patients. Com-
pared to patients who continued to smoke, patients
who quit smoking after the vascular event had a lower
risk of recurrent MACE (HR 0.64, 95%CI 0.48–0.86), of
recurrent MACE including vascular intervention (HR
0.79, 95%CI 0.67–0.95) and of all-cause mortality (HR0.62, 95%CI 0.48–0.80) (Table II). Compared to
patients who continued to smoke, patients who
never smoked had the lowest risk for recurrent
MACE (HR 0.56, 95%CI 0.45–0.81), recurrent MACE
including vascular interventions (HR 0.65, 95%CI
0.56–0.77) and of all-cause mortality (HR 0.42, 95%CI
0.33–0.53). No interaction was found between smoking
status and sex (P-value = 0.61), level of education
(P-value = 0.32) or type of vascular disease (P‐value
= 0.17) and risk of recurrentMACE. Supplemental Figure 2
shows a conventional plot of recurrent cardiovascular
disease free survival during follow-up, stratified for
smoking status.
Age at first cardiovascular event, smoking status
and survival
In Figure 2, CV disease free survival according to smoking
status is presented for patients aged ≥45 years at onset of
CV disease. At the age of 60 years, patients who quit
smoking after a first vascular event, on average had a
recurrent CV event 10 years later. Irrespective of age,
patients who quit smoking after a first CV event had a
longer life expectancy, while patients who continued to
smoke on average lived 5 years longer compared to
patients who quit smoking after the event (Figure 3).
Although the difference in CV disease free survival
between patients who quit versus those who persisted to
smoke after a first CV event at the age of≥60 or≥70 years
was less pronounced, patients who persisted to smoke
after a first CV event at the age of ≥60 or ≥70 years, had
significantly worse overall survival compared to patients
who quit (Figure 4). Sensitivity analyses in which
recurrent MACE free survival was plotted according to
type of vascular disease at baseline showed comparable
Figure 2
Risk of recurrent MACE in patients with a recent first cardiovascular event aged ≥45 years (n = 4,673) according to smoking status. Survival curve
with 95% confidence intervals, adjusted for sex, level of education, type of vascular disease, systolic blood pressure, BMI, LDL-C, diabetes, log
transformed (hs-CRP), use of antiplatelet/anticoagulant, blood pressure-lowering medication and statins. Dotted black lines indicate an average of
7.5 to 10 years less recurrent MACE free survival for patients who continue to smoke compared to patients who quit smoking after a first
cardiovascular event.
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Figures 2, 3 and 4).
Pack-years of smoking, years since smoking cessation,
and age at smoking cessation and risk of recurrent
MACE and all-cause mortality
Pack-years of smoking, years since smoking cessation
and age at smoking cessation all had a linear relation with
risk of recurrent MACE (Supplemental Figure 5). The risk
of recurrent MACE decreased when the number of years
since smoking cessation was higher or when patients
were younger when they quit smoking. Compared to
patients who smoked N5 pack-years, smoking ≤5 pack-
years was associated with a lower risk of recurrent MACE
(HR 0.73, 95%CI 0.61–0.88). Additional adjusting for
pack-years only slightly attenuated the risk of recurrent
MACE for years since smoking cessation and age at
smoking cessation. pack-years of smoking, years since
smoking cessation and age at smoking cessation also had
a linear relationship with risk of all-cause mortality
(Supplemental Figure 6). Additional adjustment for
pack-years only slightly attenuated risk of all-causemortality for years since smoking cessation and age at
smoking cessation respectively.
Discussion
Smoking is a major health issue in the current era.21
The present study shows that, irrespective of age,
cessation of smoking after a first CV event is related to
a much lower risk of recurrent vascular events and all-
cause mortality, compared to patients who continued
smoking. Patients who quit smoking after their first CV
event were found to live on average 5 years longer than
patients who continued to smoke and lived on average 10
more years without recurrent CV events.
Other studies also have quantified the life expectancy
of smokers and quitters. According to these reports, non-
smokers on average lived 10 years longer than smokers
and cessation of smoking between the age of 45 and 55
improved survival by approximately 5 years.13,14 A
smaller benefit of 1–3 life-years gained by smoking
cessation has been reported in patients with coronary
artery disease.22-24 These studies however, were based on
patients with an average age of 72 years,15 and in which
Figure 3
Risk of all-cause mortality in patients with a recent first cardiovascular event aged ≥45 years (n = 4,673) according to smoking status. Survival
curve with 95% confidence intervals, adjusted for sex, level of education, type of vascular disease, systolic blood pressure, BMI, LDL-C, diabetes, log
transformed (hs-CRP), use of antiplatelet/anticoagulant, blood pressure-lowering medication and statins. Dashed line indicates 50% survival and
dotted grey lines indicate an average of 5 years lost for patients who continue to smoke compared to patients who quit smoking after the first
cardiovascular event.
118 van den Berg et al
American Heart Journal
July 2019data collection took place between 1971 and 198024 and
1980 and 1985.23 Since then, both treatment and
secondary prevention measures have improved consider-
ably and consequently, survival of patients with manifest
arterial disease has improved. Contrary to these findings, a
more recent study from the Spanish FRENA registry
reported that cessation of smoking did not improve survival
in patients with peripheral artery disease.8 Although these
analyses tookplace in a large group of patients, resultswere
not adjusted for confounders. In the present study, no
interaction was found between type of vascular disease,
smoking status and the risk of recurrent MACE nor
mortality. In addition, we found that also in a subset of
patients with peripheral artery disease, patients who
persisted to smoke had the poorest survival (Supplemental
Figure 4), which is line with other studies.25,26
Although the proportion of patients who smoked at
onset of CV disease has decreased in the past 20 years, a
substantial proportion of patients with vascular disease
continues to smoke. In our study population of patients
with a variety of CV disease, the percentage of smokers
was approximately 20%, and decreased to approximately
10% in 2013–2014. Comparative studies are scarce,however, tobacco use is more prevalent in patients
with peripheral artery disease or aneurysm of abdominal
aorta than in patients with coronary artery disease or
cerebrovascular disease.26-29 Although the average age
did not differ, the number of pack-years was considerably
higher in patients with peripheral artery disease than in
patients with cerebrovascular of coronary artery disease.
Moreover, patients with a first acute myocardial infarc-
tion appear to be more successful in smoking cessation
than patients with peripheral artery disease.8,25,29 Per-
haps because a myocardial infarction is considered to be
more life threatening than lower limb ischemia. Another
explanation could be that peripheral artery disease is
associated with lower social economic status,30 which
subsequently is related to a higher prevalence of smoking
and lower rate of successful smoking cessation.31,32
Apart from social disparity, genome wide association
studies have identified genes associated with heavy
smoking and likelihood of smoking cessation failure,
also in patients with coronary artery disease.33,34 In
future clinical practice, these genetic markers could
perhaps assist to optimize allocation of intensive smoking
cessation interventions.
Figure 4
Risk of all-cause mortality in patients with a recent first cardiovascular event in A) patients aged ≥60 years (n = 2,536) and B) patients aged
≥70 years (n = 894) according to smoking status. Survival curves with 95% confidence intervals, are adjusted for sex, level of education, type of
vascular disease, systolic blood pressure, LDL-C, BMI, diabetes, log transformed (hs-CRP), use of antiplatelet/anticoagulant, blood pressure-
lowering medication and statins.
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cessation of smoking should be top priority in every CV
prevention setting. The effect of smoking cessation on CV
risk reduction is substantially larger in magnitude than the
medical treatment effect of a single major risk factor.35-40
Communication of the health benefits of smoking
cessation by health care providers must be emphasized,
regardless of the patient’ age or the age at first
manifestation of CV disease, in order to encourage
patients to quit. In addition to psychosocial counseling,
which enhances motivation to quit smoking and builds
coping skills to avoid relapse, pharmacotherapy can be
given to relieve nicotine withdrawal symptoms.41,42
Secondhand (smoke from burning tobacco products)and possibly also third hand smoking; i.e. residual
nicotine and other chemicals left on indoor surfaces by
tobacco smoking, are related to an increased risk of (lung)
cancer and cardiovascular disease.5,43 Cessation of
smoking thus will also benefit the next of kin, colleagues
and others in close proximity of the patient. Patient
advocacy organizations, health insurance companies and
policy makers should also have increased awareness of
the gain in life years by smoking cessation, because of
their role in effectuating a society free from tobacco-
related disease. For instance by increasing funding for in-
and out hospital smoking cessation units, prevention
programs, restriction of tobacco marketing and retail and
expansion of clean (indoor) air laws and regulations.44
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young age (b60 years) who had never smoked, appeared
to have a worse survival compared to patients who quit
smoking, even after adjusting for traditional CV risk
factors. This could be the result of or unmeasured
confounders, such as an unfavorable genetic predisposi-
tion or residual confounding such as more advanced
atherosclerosis in the non-smokers at the time of clinical
disease manifestation. In smokers, however, smoking can
be the driver of a CV event even in the absence of
generalized atherosclerosis.45,46
Strength of our study are the prospective design and
relative long duration of follow-up, up to 20 years with
limited loss to follow-up (5%). Moreover, the SMART-study
is a contemporary cohort reflecting clinical practice that
includes patients with a variety of manifestations of arterial
disease. Limitations also need to be addressed. Smoking
status at baseline was used in the analysis and patients who
persisted to smoke could have stopped, while patientswho
stopped after the vascular event could have started again.
Both scenarios however would have resulted in an
underestimation of the effect of smoking cessation on
mortality and recurrent CV events. To estimate the extent
of misclassification, smoking status during follow-up
(SMART-2 and/or SMART-3) was assessed and although
approximately 6% of the patients started or relapsed and
quitted again, themajority of patients reported that they did
not change their smoking behavior. Another potential
cause formisclassification could be that smoking status was
based on self-reported data and not objectified by
measuring urine cotinine47,48 or carbon monoxide con-
centrations in breath as done in the EUROASPIRE surveys.9
In the analyses, we have only adjusted for baseline and not
follow-up variables, which could resulted in potential
residual confounding. Although CV disease is a male
dominated disease, other limitations include the limited
number of female patients, which may limit the
generalizability of our findings. Lastly, although only
patients with a recent CV event who reached a stable
course in their disease were included, the risk of death
might be biased in the first year. However, we found the
yearly incidence of mortality in the first four years to be 1%.
In conclusion, patients who quitted smoking after a first
CV event on average gained 5 life years and delayed the
occurrence of new CV events with 10 years, compared to
patients who continued smoking. Irrespective of age,
cessation of smoking after a first CV event should be a key
objective for both patients and physicians to lower the
risk for recurrent vascular events.Acknowledgements
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